Celltrion, Inc.
Company Background
Celltrion is a South Korean pharmaceutical venture that develops "biosimilars" -- generic equivalents of biopharmaceuticals -- using microorganisms and animal cells. Remsima, a biosimilar treatment for rheumatoid arthritis, has been approved for sale in South Korea, Japan, Europe, Australia and Latin America.
Founded in 2002, Celltrion started out as a contract manufacturer for Western drug companies. It moved into biosimilars in 2008. The company's plants in South Korea can produce 200,000 liters of protein drugs per year.
In addition to well-known treatments Remsima and breast cancer drug Herzuma, the company develops and markets one to two new products a year. Celltrion plans to focus on developed markets, including Japan, the U.S. and Europe, where demand for biosimilars is growing rapidly.
Because Celltrion is a research and development-oriented company, its operating profit margin has remained high. It is one of the top companies on the Kosdaq market for startups in terms of market capitalization.
Business Summary
Financial Highlights
Dec 2022 | KRW | USD |
Revenue | 2,283.96B | 1,767.63M |
Gross Profit | 991,885.35M | 767.65M |
Operating income | 647,199.86M | 500.88M |
Income before tax | 619,117.32M | 479.15M |
Net income | 526,616.03M | 407.56M |
EBITDA | 822,487.46M | 636.55M |
Diluted EPS | 3,680.88 | 2.84 |
Dividends Per Share | 360.57 | 0.27 |
Total Assets | 5,891.65B | 4,659.27M |
Total liabilities | 1,617.44B | 1,279.12M |
Total equity | 4,139.36B | 3,273.51M |
Operating cash flow | -8,939.24M | -6.91M |
Currency in KRW | Currency in USD |
Historical Data
Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | |
Revenue | 982,074.95M | 1,128.45B | 1,849.11B | 1,893.40B | 2,283.96B |
Gross Profit | 544,684.88M | 623,118.64M | 1,016.64B | 1,050.66B | 991,885.35M |
Operating income | 322,728.11M | 381,535.86M | 718,579.05M | 744,162.54M | 647,199.86M |
Income before tax | 302,159.30M | 382,510.47M | 654,561.59M | 742,209.04M | 619,117.32M |
Net income | 245,755.01M | 301,030.34M | 517,759.53M | 569,488.02M | 526,616.03M |
EBITDA | 447,554.58M | 535,255.48M | 892,388.45M | 958,322.27M | 822,487.46M |
Diluted EPS | 1,652.66 | 2,074.44 | 3,560.57 | 3,981.47 | 3,680.88 |
Dividends Per Share | 0 | 0 | 0 | 707.01 | 360.57 |
Total Assets | 3,590.82B | 3,859.64B | 5,020.12B | 5,674.12B | 5,891.65B |
Total liabilities | 992,561.59M | 983,733.41M | 1,589.54B | 1,620.74B | 1,617.44B |
Total equity | 2,486.50B | 2,760.10B | 3,307.67B | 3,917.23B | 4,139.36B |
Operating cash flow | 354,768.82M | 468,031.66M | 342,017.88M | 901,686.05M | -8,939.24M |
Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | |
Revenue | 892.37M | 967.65M | 1,567.19M | 1,653.39M | 1,767.63M |
Gross Profit | 494.93M | 534.32M | 861.64M | 917.48M | 767.65M |
Operating income | 293.25M | 327.16M | 609.02M | 649.83M | 500.88M |
Income before tax | 274.56M | 328.00M | 554.76M | 648.12M | 479.15M |
Net income | 223.30M | 258.13M | 438.82M | 497.30M | 407.56M |
EBITDA | 406.67M | 458.98M | 756.33M | 836.84M | 636.55M |
Diluted EPS | 1.50 | 1.77 | 3.01 | 3.47 | 2.84 |
Dividends Per Share | 0 | 0 | 0 | 0.61 | 0.27 |
Total Assets | 3,218.15M | 3,337.49M | 4,621.30M | 4,773.18M | 4,659.27M |
Total liabilities | 889.55M | 850.64M | 1,463.26M | 1,363.40M | 1,279.12M |
Total equity | 2,228.44M | 2,386.70M | 3,044.90M | 3,295.25M | 3,273.51M |
Operating cash flow | 322.36M | 401.33M | 289.87M | 787.38M | -6.91M |
Valuation Measures
Dec 2022 | |
PER | 43.53 |
ROA | 9.10% |
ROE | 13.07% |
Operating margin | 28.33% |
Profit margin | 23.05% |
Management
- Chief Executive Officer & Director: Wu-Sung Ki
- Finance Director: Ho-Seop Lee
- Head-Legal & Compliance Support: Sung-Han Lee
- Vice President: Sang-Joon Lee
- Vice President: Jung-Won Yoon
Shareholders
- SEO JUNG-JIN (22.1%)
- National Pension Service of Korea (7.4%)
- Temasek Holdings Pte Ltd. (Investment Management) (4.1%)
- Celltrion, Inc. (2.6%)
- The Vanguard Group, Inc. (2.5%)
- BlackRock Fund Advisors (1.6%)
- Norges Bank Investment Management (1.1%)
- Mirae Asset Global Investments Co., Ltd. (1.0%)
- Samsung Asset Management Co., Ltd. (0.7%)
- BlackRock Advisors (UK) Ltd. (0.5%)
Contact Details
- Website:http://www.celltrion.com
- Address: 23 Academy-ro, Yeonsu-gu, Inchon, 22014, South Korea
- Phone: +82.32.850.5000
Related Companies
- Celltrion Asia Pacific Pte Ltd.
- Celltrion Group Hong Kong Ltd.
- Celltrion Biopharma Ltd.
- Celltrion Global Safety Data Center, Inc.
- Celltrion Europe Ltd.
- Vcell Healthcare Ltd.
- Takeda Pharmaceuticals (Asia Pacific) Pte Ltd.
- Celltrion Inc. Employee Stock Ownership ASSN.
- Celltrion Pharm Inc.
Competitors
- SAMSUNG BIOLOGICS Co., Ltd.
- Hikma Pharmaceuticals Plc
- Novartis AG
- Teva Pharmaceutical Industries Limited
- Amgen Inc.
- Pfizer Inc.
- AstraZeneca PLC
- Bio-Thera Solutions, Ltd. Class A
- Gilead Sciences, Inc.
- Fresenius SE & Co. KGaA
- Sanofi
- Coherus BioSciences, Inc.
- Glenmark Pharmaceuticals Limited
- GSK plc
- LG Chem Ltd.
- Otsuka Holdings Co., Ltd.
- Sam Chun Dang Pharm. Co., Ltd.
- Chemical Works of Gedeon Richter Plc
- Viatris, Inc.
- Formycon AG
- JW Pharmaceutical Corporation
- Reyon Pharmaceutical Co., Ltd.
- PharmGen Science, Inc.
- EPIRUS Biopharmaceuticals, Inc.
- EirGenix Inc
- PharmAbcine Inc.
- Bukwang Pharmaceutical Co., Ltd.
- ALTEOGEN Inc.
- Greenwich LifeSciences, Inc.
- Prestige Biologics Co., Ltd.
Copyright © 2023 FactSet Research Systems Inc. All rights reserved.
Last Updated on 21 Sep, 2023Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.